<< First  < Prev   1   2   3   Next >  Last >> 
  • 2015-06-15 20:28 | Russell Read (Administrator)
    The American Uveitis Society joined the Alliance for Eye and Vision Research (AEVR) and other societies and patient advocacy groups to co-sponsor the first ever Congressional Briefing on Uveitis. AUS member Gary N. Holland, MD, Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and Jack H. Skirball Chair in Ocular Inflammatory Diseases, was a featured speaker.

    Left to right: Gary N Holland MD (Jules Stein Eye Institute, David Geffen School of Medicine at UCLA), Janine Austin Clayton MD (National Institutes of Health Associate Director for Research on Women’s Health), and James Jorkasky ( Executive Director of AEVR/NAEVR).

     Full details of the briefing can be found on the AEVR website.
  • 2015-05-09 07:43 | Russell Read (Administrator)

    The 13th Congress of the International Ocular Inflammation Society will be held in San Francisco from September 25 to 27, 2015. This will be the first IOIS Congress to be held in the US. More than 25 societies focused on ocular inflammation will host sessions during the three day meeting along with IOIS Sections focused on all aspects of ocular immunology and disease. Further details can be found at the Congress website.

  • 2015-03-22 15:44 | Russell Read (Administrator)

    The National Eye Institute (NEI and US Food and Drug Administration (FDA) are holding a public Workshop on Endpoints for Ocular Inflammatory Diseases on the campus of the NIH on March 26, 2015 in the Masur Auditorium.

    Details regarding the meeting can be found here:

    2015 NEI/FDA Endpoints Workshop

  • 2015-02-03 12:00 | Russell Read (Administrator)

    The MUST Research Group, which successfully completed the Multicenter Uveitis Steroid Treatment (MUST) Trial is conducting two new trials, the Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial and the Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy (MERIT) Trial. Both are funded by the National Eye Institute. POINT will compare the relative efficacy of three common approaches for the regional treatment of uveitic macular edema, periocular and intravitreal triamcinolone acetonide, and the dexamethasone intravitreal implant. MERIT will evaluate the relative efficacy of intravitreal ranibizumab and intravitreal methotrexate and the dexamethasone intravitreal implant for the treatment of uveitic macular edema persisting after intravitreal triamcinolone acetonide. The POINT Trial will be initiated in Spring 2015 in clinical centers that are currently following participants in the MUST Trial Follow-up Study and to have new clinical centers selected and preparing for start-up by the time of our Research Group meeting in June 2015. The MERIT Trial will begin approximately 12 months after the start of POINT; the trials will run concurrently until POINT is completed.

    Those interested in being a clinical center for POINT and MERIT should visit the Clinic Applications site or read the attached document to learn more.

  • 2015-01-21 15:56 | Russell Read (Administrator)

    Abstract submission for FOCIS 2015 closes Wednesday, January 15. 

    The American Uveitis Society is a member society of FOCIS, the Federation of Clinical Immunology Societies.

  • 2015-01-20 17:46 | Russell Read (Administrator)

    Interesting application for the iPhone that allows you to help a low vision person with a specific issue via a video/audio link on your iPhone.

    Be My Eyes - iTunes App Store Link

  • 2015-01-16 10:40 | Russell Read (Administrator)

    The American Uveitis Society is proud to reveal its most extensive update to since its inception. This complete revamping will result in enhanced membership customer service by allowing members to view and update their profile information, track their membership status and pay dues online, and provides an enhanced Uveitis Specialist Directory through which patients can easily access clinician contact information.

<< First  < Prev   1   2   3   Next >  Last >> 

Copyright © The American Uveitis Society
All rights reserved

700 18th Street South Suite 601
Birmingham Alabama 35233 USA

The American Uveitis Society is a 501(c)6 non-profit organization

Powered by Wild Apricot Membership Software